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Aims Cardiac resynchronization therapy (CRT) is a disease-modifying therapy in patients with chronic heart failure
(CHF). Current guidelines ascribe CRT eligibility on three parameters only: left ventricular ejection fraction (LVEF),
QRS duration, and New York Heart Association (NYHA) functional class. However, one-third of CHF patients
does not benefit from CRT. This study evaluated whether 123I-meta-iodobenzylguanidine (123I-mIBG) assessed car-
diac sympathetic activity could optimize CRT patient selection.
...................................................................................................................................................................................................
Methods
and results
A total of 78 stable CHF subjects (age 66.8 ± 9.6 years, 73% male, LVEF 25.2 ± 6.7%, QRS duration 153 ± 23 ms,
NYHA 2.2 ± 0.7) referred for CRT implantation were enrolled. Subjects underwent 123I-mIBG scintigraphy prior to
implantation. Early and late heart-to-mediastinum (H/M) ratio and 123I-mIBG washout were calculated. CRT re-
sponse was defined as either an increase of LVEF to >35%, any improvement in LVEF of >10%, QRS shortening to
<150 ms, or improvement in NYHA class of >1 class. In 33 patients LVEF increased to >35%, QRS decreased
<150 ms in 36 patients, and NYHA class decreased in 33 patients. Late H/M ratio and hypertension were independ-
ent predictors of LVEF improvement to >35% (P= 0.0014 and P¼ 0.0149, respectively). In addition, early H/M
ratio, LVEF, and absence of diabetes mellitus (DM) were independent predictors for LVEF improvement by >10%.
No independent predictors were found for QRS shortening to <150 ms or improvement in NYHA class.
...................................................................................................................................................................................................
Conclusion Early and late H/M ratio were independent predictors of CRT response when improvement of LVEF was used as
measure of response. Therefore, cardiac 123I-mIBG scintigraphy may be used as a tool to optimize selection of sub-
jects that might benefit from CRT.
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Introduction
Chronic heart failure (CHF) is a life-threatening syndrome. Despite
pharmacological therapy induced improvement, the prognosis
remains poor with a mortality rate of 20% during the first years.1 Left
ventricular (LV) dyssynchrony with QRS prolongation is present in
>25% of the subjects with CHF. LV dyssynchrony has emerged as an
important marker for the progression of CHF and LV remodelling
with detrimental effects on cardiac function, such as systolic and dia-
stolic LV dysfunction. In addition, LV dyssynchrony appears to play a
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major role in the pathophysiology of CHF.2 Cardiac resynchroniza-
tion therapy (CRT) has been shown to improve left ventricular ejec-
tion fraction (LVEF), reduce hospitalization due to heart failure (HF),
and decrease all-cause mortality in selected CHF patients.3–5 CRT is
currently recommended as a Class IA in symptomatic CHF subjects,
when LVEF is <_35%, sinus rhythm is present, and QRS is >_150 ms.6,7
However, one-quarter to one-half of the subjects who receive a
CRT are ‘non-responders’ and do not benefit from CRT device im-
plantation.8,9 For example, the Multicenter InSync Randomized
Clinical Evaluation (MIRACLE) trial showed no therapeutic benefit of
CRT in 33% of subjects using a clinical composite score including all-
cause mortality, HF hospitalization, New York Heart Association
(NYHA) functional class, and clinical performance scores.10 Non-
response to therapy has remained the Achilles’ heel of CRT over the
years and is clearly multifactorial involving multiple pre-, peri-, and
post-implantation factors.11 As the implantation of CRT devices is
associated with the risk of device malfunction, peri-procedural com-
plications,12,13 and relatively high costs, the search for other discrim-
ination factors to optimize the current selection criteria for CRT
device implantation is essential.
Despite two decades of development of CRT, a consensus of who
will respond to CRT has not been reached. In part, this can be
explained by the fact that clinical trials and registries used a variety of
different outcome measures without a unified/harmonized (compos-
ite) endpoint.14 Early studies used parameters reflecting functional
improvement (i.e. VO2 max, 6-min walk test, and NYHA functional
class).15,16 More recent CRT trials used HF hospitalization and death
as a more objective, hard clinical endpoints.3,4 Besides clinical events
and mortality, surrogate outcomes such as LV remodelling measures
[i.e. improvement of LVEF, LV end-systolic volume (LVESV), and LV
end-diastolic volume (LVEDV)] were also used in clinical trials.
Because of the multiple available parameters and because of the lack
of consensus in defining CRT response we used three different types
of response: echocardiographic (improvement of LVEF), electro-
graphic (QRS duration), and functional improvement (NYHA func-
tional class).
The cardiac sympathetic system is one of the neurohormonal
compensation mechanisms that play an important role in the patho-
genesis of CHF with reduced LVEF. Patients with CHF have increased
cardiac sympathetic activity with increased exocytosis of norepineph-
rine (NE) from the presynaptic vesicles. Initially, b-adrenergic recep-
tor (AR) stimulation by increased NE levels helps to compensate for
impaired myocardial function, but long-term NE excess gives rise to a
downregulation and decrease in the sensitivity of post-synaptic b-
AR.17,18 This downregulation leads to LV remodelling and is associ-
ated with increased mortality and morbidity.19 Cardiac 123I-meta-
iodobenzylguanidine (123I-mIBG) scintigraphy has been widely used
for non-invasive assessment of cardiac sympathetic function in CHF.
123I-mIBG is an NE analogue which is concentrated and stored in the
presynaptic sympathetic myocardial nerve terminals in a fashion simi-
lar to NE.20 It has been demonstrated that impaired cardiac sympa-
thetic activity as assessed with 123I-mIBG is associated with poor
outcome in CHF.21–24
Several studies have shown that CRT improves 123I-mIBG assessed
cardiac sympathetic activity. Available data demonstrated that CRT
responders have a rebalance in cardiac autonomic function as struc-
tural reverse remodelling (i.e. increase of LVEF) may also induce
reverse modulation of cardiac sympathetic activity and rebalance of
cardiac autonomic activity.25–28 Therefore, cardiac 123I-mIBG scintig-
raphy may have a potential role in predicting CRT response. As far as
we know the association between cardiac sympathetic activity and
CRT response defined as improvement of LVEF has never been eval-
uated previously in a multicentre study. Therefore, the purpose of
the study was to evaluate whether 123I-mIBG assessed cardiac sympa-
thetic activity could optimize CRT patient selection.
Methods
Study population
Design
All subjects underwent planar cardiac 123I-mIBG scintigraphy prior to
CRT implantation and were followed for the occurrence of the primary
endpoint 1 year ± 2 months after CRT implantation. The primary end-
point for this study was response to CRT defined as increase of LVEF to
>35%, any improvement in LVEF of >10%, QRS shortening to <150 ms,
and improvement in NYHA functional class of at least one class.
We combined data from two previous prospective studies from the
Netherlands22 and Italy,29 both evaluated the prognostic role of cardiac
123I-mIBG scintigraphy in subjects with stable CHF who were referred for
implantable cardiac defibrillator (ICD) implantation. The inclusion criteria
of both original studies were (i) LVEF <_35%, (ii) NYHA functional Class II
or III, (iii) stable HF and treated with optimal medical therapy for at least
3 months according to the European HF guidelines,7 and (iv) pacemaker-
naive. Both studies were approved by the local institutional review boards
and conducted according to the principles of the International
Conference on Harmonization–Good Clinical Practice. All subjects pro-
vided written informed consent before participation. In the original stud-
ies, some subjects did not have an indication for ICD implantation only
but were also eligible for CRT (i.e. QRS duration > 150 ms, LVEF <_ 35%,
NYHA functional Class II or III). Therefore, these subjects received an
integrated device with ICD and CRT function (i.e. CRT-D) as recom-
mend by the ESC guidelines.6 In the current study, we only enrolled those
subjects with CRT-D implantation. The follow-up data of LVEF, QRS dur-
ation, and NYHA functional class in the original studies were prospective-
ly collected from outpatient visits, medical reports, and telephone calls.
123I-mIBG scintigraphy acquisition and analysis
To block uptake of free 123I by the thyroid gland, subjects were pre-
treated with 250 mg oral potassium iodide or 5% Lugol solution 30 min
before intravenous injection of 150–185 MBq123I-mIBG (AdreviewVR , GE
Healthcare). Fifteen minutes (i.e. early) and 4 h (i.e. late) after administra-
tion of 123I-mIBG, 10-min planar images were acquired from an anterior
thoracic view (128 128 or 256 256 matrix) with the subject in supine
position using a 20% window centred at 159 keV.
All planar 123I-mIBG were analysed by two experienced observers
(D.O.V. and V.F.). H/M ratio was calculated from planar 123I-mIBG images
using a manually drawn region of interest (ROI) over the heart and a
fixed rectangular mediastinal ROI (Figure 1).30 To correct for differences
in gamma camera-collimator combination, institutional early and late pla-
nar H/M ratios were converted to standardized medium energy (ME) col-
limator values by using conversion coefficients from our previous 123I-
mIBG cross-calibration phantom study.31 The washout (WO) was
defined by:
WO ¼ ðearly H=M late H=MÞðearly H=MÞ
 
 100:
2 D.O. Verschure et al.
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CRT implantation
After myocardial 123I-mIBG imaging, the CRT-D device was implanted in
the participating institutions. Although pacemaker -lead placement was at
the discretion of each institution, placement in infarcted segments was
not recommended and avoided as much as possible. Testing of sensing
and pacing, as well as defibrillation thresholds was performed according
to local protocols.
Clinical follow-up
All subjects received standard clinical care and were followed up 1 year
after CRT implantation with evaluation by echocardiography (LVEF),
electrocardiogram, and NYHA functional capacity. Changes in LVEF,
QRS duration, and NYHA functional class between baseline and 1-year
follow-up were used as parameters of CRT response.
Statistical analysis
All continuous variables are expressed as mean ± standard deviation.
Differences between groups for continuous data were compared using
unpaired T-test. Efficacy analysis was performed using logistic regression
for the primary endpoint with a variety of parameters [i.e. age, hyperten-
sion, DM, QRS duration, NYHA functional class, LVEF, early and late
standardized H/M ratio, 123I-mIBG WO]. Forward elimination deter-
mined the combination of parameters that most influenced the model. A
P-value <0.05 was considered to indicate a statistically significant differ-
ence. Receiver operating characteristic (ROC) analysis was performed
using parameters listed above to predict any improvement in LVEF >10%
and improvement of LVEF to >35%. ROC curves were created with mul-
tiple significant variables combined, and areas under the curve (AUC)
with 95% confidence interval (CI) were calculated. The differences in
AUC for the different ROC curves were compared using whole model
tests and pairwise comparisons. The probability of CRT response was
assessed using the ROC-derived optimal cut-off values and the associated
logistic curves. The response rate to CRT treatment was analysed by a
multi-variable logistic regression model.32 Mathematical calculation for
creating ROC analysis and models was based on Mathematica 12
(Wolfram Research Inc., Champaign, IL, USA). Other statistical analyses
were performed with SPSS, release 25.0 (SPSS Inc., Chicago, IL, USA
2017).
Results
In total, 78 stable CHF subjects [the Netherlands (n= 42) and Italy
(n= 36)] referred for CRT-D implantation were enrolled. Baseline
characteristics of the study population are shown in Table 1. The
mean age was 66.8 ± 9.6 years and 73% was male. Almost 56% of the
subjects had ischaemic heart disease. Mean baseline NYHA functional
class was 2.4 ± 0.6 and mean LVEF was 25.2± 6.7%. The mean early
standardized H/M ratio was 2.04± 0.37, late standardized H/M ratio
was 1.82 ± 0.36, and 123I-mIBG WO was 10.6± 10.8. There was a dif-
ference in early and late H/M ratio between the population in the
Netherlands and Italy. The incidence of hypertension was higher in
the Italian subjects. Seventy-six subjects completed the 1-year
follow-up. Two subjects died during follow-up due to sudden cardiac
death (SCD), 9 (late H/M ratio: 1.56) and 11 (late H/M ratio: 1.26)
months after enrolment, respectively. These two subjects were quali-
fied as ‘non-responder’ in the statistical analysis.
Predictors of CRTresponse after 1-year
follow-up
Response defined as increase of LVEF
In eight subjects no follow-up echocardiography was performed due
to transfers to other institutions. In total, 53 subjects showed any im-
provement of LVEF 1 year after CRT device implantation. A substan-
tial part of the observed changes in LVEF after 1-year follow-up was
well within the echocardiographic intra- and inter-observer variation
(i.e. 7.6% and 8.3%, respectively).33 The mean change in LVEF was
4.6± 15.3% (Figure 2). In total, 33 subjects showed an LVEF >35%
after 1-year follow-up. The baseline characteristics of responders and
non-responders are shown in Table 2. There was a significant differ-
ence in late H/M ratio between responders and non-responders
(2.00 ± 0.40 vs. 1.67 ± 0.25, respectively, P= 0.008). When improve-
ment in LVEF was dichotomized <_35% (non-responder) and >35%
(responder), logistic regression analysis showed that late H/M ratio
[OR 18.19 (95% CI 3.06–108.23), P= 0.0014] and hypertension [OR
0.23 (95% CI 0.07–0.75), P= 0.0149] were independent predictors of
CRT response. This outcome is mainly driven by the results of the
Dutch population (data not shown). Figure 3A shows ROC AUC
curves for late H/M and hypertension in relation to late H/M ratio.
Although the ROC AUC was higher for the combination of late H/M
and hypertension compared with late H/M ratio alone, the difference
in ROC AUC did not reach statistical significance [0.802 (95% CI
0.671–0.889) vs. 0.746 (95% CI 0.608–0.847), P= 0.16] (Figure 3A).
When CRT response was defined as any improvement in LVEF of
>10%, early H/M ratio [OR 51.51 (95% CI 5.81–456.81), P= 0.0004],
DM [0.15 (95% CI 0.04–0.56), P= 0.0049], and baseline LVEF [OR
0.89 (95% CI 0.80–0.99), P= 0.0281] were independent predictors of
CRT response. When ROC analysis was performed with these three
variables (a) the combination of early H/M ratio, DM, and baseline
LVEF, (b) early H/M ratio, and (c) LVEF separately, the AUC was
0.838 (95% CI 0.726–0.911), 0.755 (95% CI 0.623–0.851), and 0.635
Figure 1 Example of planar 123I-mIBG images of 68-year-old pa-
tient with ischaemic heart failure with a calculated standardized H/
M ratio of 1.62. A manual drawn ROI is placed over the heart (H).
A fixed rectangular ROI is positioned in the mediastinum (M) in rela-
tion to the lung apex, the lower boundary of the upper mediasti-
num, and the midline between the lungs.
Relation between cardiac 123I-mIBG scintigraphy and response to CRT 3
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(95% CI 0.498–0.754), respectively (P= 0.0056 for a vs. c; P= 0.065
for a vs. b; P= 0.21 for b vs. c) (Figure 3B). Figure 4 illustrates that
when CRT response was defined as any improvement in LVEF of
>10%, response rate is higher when DM is not present, early H/M
ratio is high, and baseline LVEF is low.
The probability of LVEF improvement to >35% and any improve-
ment in LVEF >10% using H/M ratio are shown in Figure 5A. The opti-
mal H/M ratio for LVEF improvement was 2.0 with a ROC AUC was
0.746 and 0.755 for both late and early H/M ratios, respectively
(Figure 5B). The probability of CRT response using the ROC-derived
optimal cut-off values showed that a 2.0 threshold for the late H/M
ratio corresponded with a 60% probability of LVEF improvement to
>35%. More important is that higher late H/M thresholds result in
higher probability of CRT response. For example, the probability of
CRT response increased to 80% at a threshold of 2.5 for the late H/
M ratio (Figure 5A).
Response defined as shortening of QRS duration
The mean shortening of QRS duration was 12.0± 26.0 ms. In total,
36 subjects showed shortening of QRS <150 ms duration 1 year after
CRT implantation. There was no significant difference in early and
late H/M ratio and 123I-mIBG WO between responders and non-
responders (data not shown). When shortening of QRS duration
was used as a measure of CRT response, logistic regression analysis
was not able to identify an independent predictor of response (data
not shown).
Response defined as decrease of NYHA functional class
In total, 33 subjects reported improvement of NYHA functional class
with at least one class 1 year after CRT implantation. There was no
significant difference in early and late H/M ratio and 123I-mIBG WO
between responders and non-responders (data not shown). When
improvement in NYHA functional class was used as a marker of CRT
response, logistic regression analysis was not able to identify an inde-
pendent predictor of CRT response (data not shown).
Response defined as increase of LVEF to 35%, decrease
of QRS duration 150 ms, or decrease of NYHA
functional class
In total, 65 subjects showed improvement 1 year after CRT implant-
ation of at least one of the following variables: LVEF >35%, QRS dur-
ation <150 ms, or NYHA functional class. There was no significant
difference in early and late H/M ratio and 123I-mIBG WO between
responders and non-responders (data not shown). Using these com-
bined response criteria, logistic regression analysis was not able to
identify an independent predictor of CRT response (data not shown).
Discussion
Our study is the first multicentre study that evaluated cardiac 123I-
mIBG scintigraphy in relation CRT response 1 year after CRT im-
plantation using standardized H/M ratios. The results of this study
show that a late H/M ratio is an independent predictor of CRT re-
sponse defined as increase of LVEF to >35%. Although hypertension
was also shown to be an independent predictor, the combination of
hypertension and late H/M ratio did not result in a statistical signifi-
cant change in the ROC AUC.
LVEF is a strong predictor of prognosis in HF patients. Agra
Bermejo et al.34 showed that HF patients with a reduced LVEF
....................................................................................................................................................................................................................
Table 1 Patients baseline characteristics of total patient population and per institution
All (n5 78) Netherlands (n542) Italy (n5 36) P-value
Age (years) 66.8 ± 9.6 65.3 ± 8.5 68.6 ± 10.5 0.118
Male gender (%) 57 (73) 30 (71) 27 (75) 0.723
Ischaemic heart disease (%) 34 (44) 16 (38) 18 (50) 0.291
NYHA class 2.4 ± 0.6 2.3 ± 0.5 2.4 ± 0.8 0.707
LVEF (%) 25.2 ± 6.7 22.9 ± 6.5 28.0 ± 6.0 0.756
QRS time (ms) 157 ± 26 153 ± 23 163 ± 29 0.254
Medical history
Hypertension (%) 51 (66) 20 (48) 31 (86) <0.001
Diabetes mellitus (%) 28 (36) 12 (29) 16 (44) 0.145
Dyslipidaemia (%) 31 (40) 13 (31) 18 (50) 0.087
Medication
Beta-blocker (%) 66 (85) 36 (86) 30 (83) 0.771
ACE-I/ARB (%) 63 (81) 38 (91) 25 (69) 0.019
MRA (%) 30 (39) 14 (33) 16 (44) 0.315
Loop diuretics (%) 64 (82) 31 (74) 33 (92) 0.080
Planar 123I-mIBG
Early H/M ratio 2.04 ± 0.37 2.14 ± 0.41 1.93 ± 0.27 0.020
Late H/M ratio 1.82 ± 0.46 1.86 ± 0.41 1.77 ± 0.29 0.015
123I-mIBG WO 10.6 ± 10.8 12.8 ± 10.1 8.1 ± 11.2 0.299
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensine receptor blocker; MRA, mineralocorticoid receptor antagonist.
4 D.O. Verschure et al.
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who had significant improvement of LVEF after treatment, had a
more favourable prognosis (less hospitalization and mortality)
compared with patients without improvement of LVEF. Recently a
meta-analysis, including 24 observational studies with total 11 018
CHF subjects treated according to recommended drug therapy,
CRT, and/or intra-cardiac defibrillator, showed that CHF patients
with improved LVEF (n= 2663) had significantly lower risks of
mortality and appropriate shocks compared with patients with
persistently reduced LVEF (n= 8355).35 This suggests that im-
provement of LVEF is a relevant parameter for survival and
should therefore be included in the definition of CRT response.
In the present study, we evaluated increase of LVEF to >35% and
any improvement in LVEF of >10% as LVEF response criteria. As
an LVEF of 35% is the cut-off point for the decision whether a
CRT or ICD device should be implanted or replaced (i.e. end of
life battery) in subjects with CHF, the first tested LVEF response
-20
-10
0
10
20
30
40
Delta LVEF (%)
Figure 2 Waterfall plot of change of LVEF between baseline and 1-year follow-up. Dashed blacklines indicate the boundaries of the echocardio-
graphical intra- and inter-observer variation.
....................................................................................................................................................................................................................
Table 2 Patients baseline characteristics of CRTresponders vs. CRT non-responders using LVEF improvement to
>35%
All (n5 78) Responders (n533) Non-responders (n5 37) P-value
Age (years) 66.8 ± 9.6 68.0 ± 8.6 64.7 ± 10.4 0.476
Male gender (%) 57 (73) 21 (64) 28 (76) 0.273
Ischaemic heart disease (%) 34 (44) 11 (33) 20 (54) 0.081
NYHA class 2.4 ± 0.6 2.5 ± 0.7 2.2 ± 0.6 0.193
LVEF (%) 25.2 ± 6.7 25.0 ± 6.8 26.0 ± 7.1 0.591
QRS time (ms) 157 ± 26 162 ± 26 152 ± 27 0.748
Medical history
Hypertension (%) 51 (66) 17 (52) 30 (81) 0.004
Diabetes mellitus (%) 28 (36) 8 (24) 19 (51) 0.020
Dyslipidaemia (%) 31 (40) 9 (27) 20 (54) 0.023
Medication
Beta-blocker (%) 66 (85) 28 ( 85) 31 (84) 0.903
ACE-I/ARB (%) 63 (81) 28 (85) 28 (75) 0.338
MRA (%) 30 (39) 11 (33) 15 (41) 0.533
Loop diuretics (%) 64 (82) 26 (79) 33 (89) 0.233
Planar 123I-mIBG
Early H/M ratio 2.04 ± 0.37 1.91 ± 0.28 2.18 ± 0.39 0.127
Late H/M ratio 1.82 ± 0.46 2.00 ± 0.40 1.67 ± 0.25 0.008
123I-mIBG WO 10.6 ± 10.8 11.5 ± 1.89 8.8 ± 10.4 0.727
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensine receptor blocker; MRA, mineralocorticoid receptor antagonists.
Relation between cardiac 123I-mIBG scintigraphy and response to CRT 5
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importance.
In the landmark trials, the selection of patients was mainly based
on QRS duration.3,36 Retrospective analyses have shown that
patients with left bundle branch block morphology have a higher
chance to respond to CRT.37,38 As a consequence, both QRS dur-
ation and morphology are mentioned as an one of the inclusion crite-
ria for CRT in the most recent guidelines.6,7 However, a substantial
Figure 3 (A) AUC curves for late H/M ratio (blue) and combination of late H/M ratio and hypertension (red) for predicting increase of LVEF to
>35%. (B) AUC curves for combined use of early H/M ratio, LVEF, and diabetes mellitus (DM) (red), early H/M ratio (blue), and LVEF (yellow) for
predicting increase of LVEF by >10%.
Figure 4 Prediction model of increase of LVEF with >_10% created using the three-variable logistic model with baseline LVEF, early H/M ratio, and
diabetes mellitus (DM). The response rate is higher when DM is not present, early H/M ratio is higher, and baseline LVEF is lower.
6 D.O. Verschure et al.
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percentage of CHF patients does not benefit from CRT implantation,
so-called ‘non-responders’.8–10 It is anticipated that number of CHF
subjects with a CRT indication will increase.13,39 Therefore, the prob-
lem of non-response to CRT will be increasingly important, at least
from a numerical point of view. The response to CRT is multifactor-
ial, including pre-implantation factors such as aetiology of CHF, QRS
duration, and mechanical dyssynchrony.14,40,41 In addition, peri-
implantation factors such an optimal delivery of CRT and targeted
lead position are essential for response to CRT. Myocardial scar in
the region of the LV pacing lead is an independent determinant of
long-term prognosis in ischaemic HF.42 Finally, post-implantation fac-
tors such as arrhythmia and device programming influence the re-
sponse to CRT.14 Several clinical and echocardiographic variables
have been evaluated to predict response to CRT. Ischaemic aeti-
ology, male gender, NYHA functional Class IV, severe mitral regurgi-
tation, left atrial dilatation, and a short interventricular mechanical
delay have been associated with worse echocardiographic and clinical
outcomes.4,43 However, their contributions to the selection of
patients are limited as most of these variables were not independent
predictors of the response to CRT.
Previous studies that evaluated cardiac 123I-mIBG scintigraphy in
relation to long-term CRT response were single centre with relative
small numbers of CHF patients.25–28,44–46 Recently, the large single
centre BETTER-HF study showed in CHF patients (n= 121) that the
late H/M ratio was an independent predictor of CRT response
defined as LV remodelling with 15% reduction of LVESV (regression
coefficient 2.906, 95% CI 0.293–3.903, P= 0.029).47 These results are
in line with our study showing that LV remodelling (i.e. improvement
of LVEF) was associated with the late H/M ratio. Furthermore, the
BETTER-HF study showed that the late H/M ratio was an independ-
ent predictor of long-term clinical outcome (combined endpoint of
cardiac mortality, cardiac transplantation, HF hospitalization: hazard
ratio 0.033, 95% CI 0.005–0.880, P= 0.040). Tanaka et al.48 showed
that in CHF (n= 50) mechanical dyssynchrony is associated with 123I-
mIBG assessed cardiac sympathetic activity. In patient with dyssyn-
chrony late H/M ratio was lower compared to patients without dys-
synchrony (1.62± 0.31 vs. 1.82 ± 0.36, P< 0.05). Furthermore,
patients with both dyssynchrony and late H/M ratio >_1.6 had a higher
frequency of CRT response and a favourable outcome after 3 years.
Interestingly, Erol-Yilmaz et al.25 showed that parallel to significant
functional (NYHA class) improvement and echocardiographic re-
verse remodelling, CRT induces favourable changes in the neurohu-
moral system (i.e. increase of late H/M ratio), supporting the notion
that structural reverse remodelling (i.e. increase of LVEF) may also in-
duce reverse modulation of cardiac sympathetic activity and rebal-
ance of cardiac autonomic activity.
In line with the previous studies, the results of our study showed
that late H/M ratio is an independent predictor of reverse remodel-
ling of LVEF (i.e. increase of LVEF to >35%). However, late H/M ratio
is not associated with increase of LVEF >10%. In addition to baseline
LVEF and DM, early H/M was an independent predictor for increase
of LVEF >10%. Although the precise mechanism is unknown, the cor-
relation between cardiac innervation (i.e. H/M ratio) and CRT re-
sponse is highly interesting. Although a number of other variables
have been suggested to improve CRT patient selection, only a few
have seen wide-spread implementation. Most other imaging
Figure 5 (A) Probability of LVEF improvement to >35% using late H/M ratio (blue) and LVEF improvement by >10% (orange) using early H/M
ratio. The optimal threshold of 2.0 for late H/M ratio corresponded with 60% probability of LVEF improvement to >35%. For early H/M ratio a
threshold corresponded with 49% probability of LVEF improvement by >10%. (B) ROC analysis red dots denote the probability of LVEF improve-
ment when H/M ratio is 2.0. ROC AUC was 0.746 and 0.755 using late and early H/M ratios, respectively.
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modalities focus on mechanical and anatomical information, whereas
the neurohumoral information gained from cardiac 123I-mIBG scintig-
raphy adds a unique perspective on the pathophysiology of HF in gen-
eral and most likely for CRT response in particular.
Our study has some limitations. We used data from two cohort
studies and analysed them retrospectively. As data about LVESV and
LVEDV were not recorded we have only the LVEF as echocardio-
graphic measurement. Furthermore, the loss of echocardiographic
data of eight subjects during follow-up may have influenced the out-
come. For assessment of functional impact we used the relatively
subjective NYHA functional class, although a 6-min walk test would
be more objective. However, these data were not available. In add-
ition, we qualified two subjects that died during follow-up due to
SCD as ‘non-responder’. This qualification could potentially influence
outcome. However, exclusion of these two subjects from the analy-
ses did not change the outcome of the analyses (data not shown).
Infarct size and location can be of influence of lead implantation and
consequently with response. Pacemaker leads were placed according
to the discretion of the cardiologist responsible of the CRT-D im-
plantation and in line with the most recent guidelines, avoiding as
much as possible infarcted myocardial areas. However, in a large
number subjects exact information on the pacemaker lead in relation
possible myocardial scar could not be retrieved in this retrospective
study. Therefore, the available data were too small to perform an ad-
equate multivariate analysis. We were therefore not able to assess
the impact of pacemaker lead placement on CRT response. Remains
that myocardial perfusion imaging with single-photon-emission com-
puted tomography or positron emission tomography could be of
help to locate possible infarcted myocardium and thereby help guide
pacemaker lead placement.
Nonetheless, we feel that despite these limitations our data reflect
clinical practice and could be useful to better identify CRT respond-
ers from non-responders.
Conclusion
In stable CHF 123I-mIBG assessed cardiac sympathetic activity pre-
dicts CRT response defined as improvement of LVEF after follow-up
of 1 year. Therefore, these results may help selecting CHF patients
eligible for CRT and consequently reduce the percentage of non-
response to CRT.
Trying to put our findings in a clinical perspective, we conclude
that for CHF patients eligible for CRT based on the current criteria in
combination with a late H/M ratio of at least 2.0 there is little doubt
about clinical response and therefore strengthens the CRT indication
(i.e. predicted response increasing from 60% and higher with higher
late H/M ratios). However, in CHF patients with a late H/M ratio of
1.8 or less CRT indication should be reconsidered (i.e. predicted re-
sponse declining from 50% and lower with lower late H/M ratios).
Conflict of interest: none declared.
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